Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 6/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30761194 | 0.87 | SIRT3 (0.47) | DHODHCYP11B2CYP11B1ABL1GPBAR1 | |
| SCHEMBL31031733 | 0.82 | DHODH (0.45) | DHODHCYP11B2CYP11B1ABL1MAP4K1 | |
| SCHEMBL30761147 | 0.79 | GRM5 (0.47) | ABL1MAP4K1 | |
| SCHEMBL4778479 | 0.78 | KMO (0.53) | DHODHCYP11B2CYP11B1 | |
| SCHEMBL30761182 | 0.78 | GRM5 (0.56) | — | |
| SCHEMBL30761174 | 0.77 | GRM5 (0.60) | — | |
| SCHEMBL1794081 | 0.77 | NPC1 (0.58) | — | |
| SCHEMBL4778496 | 0.76 | ABL1 (0.41) | ABL1 | |
| SCHEMBL29238864 | 0.75 | CYP11B2 (0.45) | CYP11B2CYP11B1ABL1MAP4K1KIT | |
| SCHEMBL4772052 | 0.75 | ALOX15 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | GRM2, GRM1, GRM3 | DHODH 3540/4885CYP11B2 2896/4885CYP11B1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.